Anju’s Feasibility Flex in TA Scan Wins Best of Show at SCOPE Summit Europe

FORT LAUDERDALE, Fla., Oct. 31, 2024 /PRNewswire/ — Anju Software recently introduced Feasibility Flex, the newest feature in the flagship product, TA Scan, designed to transform clinical trial feasibility assessments. This powerful tool addresses the rising complexities of trial design and execution, providing unmatched flexibility and precision to enhance trial planning. Feasibility Flex recently won Best of Show at SCOPE Summit Europe for its innovative impact on life sciences. The award, chosen by attendees, celebrates exhibitors advancing clinical research with meaningful solutions.

Feasibility Flex allows clinical teams to input and adjust key trial parameters, ensuring more accurate enrollment projections and informed site selection. This adaptability is critical in modern trials, where fluctuating regulations, global patient recruitment challenges, and intricate protocols add layers of complexity and unpredictability. The feature harnesses TA Scan’s high quality clinical data alongside user insights, such as signature site lists and country-level start-up timelines, to deliver precision insights for strategic and operational planning.

Key capabilities of Feasibility Flex include:

  • Leveraging Data for Precision Enrollment: Build enrollment scenarios with high-quality data, enhanced by user insights, for accurate and tailored enrollment projections.
  • Dynamic Site and Country Intelligence: Fine-tune projections and site recommendations by adjusting parameters in real time. Visualize projected country-level timelines, with options to customize regulatory delay.
  • Predictability in Trial Planning: Gain comprehensive insights for informed trial planning, resulting in more efficient and predictable trials.

Feasibility Flex empowers teams to make data-driven decisions faster and with greater confidence. In an industry where only 10-12% of drugs reach the market, this feature provides an essential edge, helping organizations avoid delays, manage costs, and reduce inefficiencies.

Discover how TA Scan can transform your trial planning. Visit our website or contact our team at info@anjusoftware.com to schedule a demo today!

About Anju Software
Anju is a customer-first organization delivering adaptable life science solutions for clinical researchmedical affairs, and data science. TrialMasterIRMS MAX, and TA Scan, the company’s flagship products, lead the way in reducing complexities in the drug and device discovery and commercialization process. With a team of industry experts and a diverse suite of versatile products, Anju empowers clients to drive innovation, efficiency, and compliance. Anju is a portfolio company of Valsoft serving the worldwide pharmaceutical, biotech and contract research Life Sciences markets.

Media Contact
John F. Kouten
JFK Communications, Inc.
+1 609.241.7352
jfkouten@jfkhealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/anjus-feasibility-flex-in-ta-scan-wins-best-of-show-at-scope-summit-europe-302292973.html

SOURCE Anju Software

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

48 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

49 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

53 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

53 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

53 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

53 minutes ago